Literature DB >> 31155927

Downregulation of WW domain-containing oxidoreductase leads to tamoxifen-resistance by the inactivation of Hippo signaling.

Juan Li1,2,3, Xuefei Feng1,2,3, Canyu Li4, Jie Liu1,2, Pingping Li1,2, Ruiqi Wang1,2, He Chen1,2, Peijun Liu1,2.   

Abstract

Entities:  

Keywords:  Breast cancer; Hippo; WW domain-containing oxidoreductase; cell; resistance; tamoxifen

Mesh：

Substances：

Year:  2019        PMID： 31155927      PMCID： PMC6879770          DOI： 10.1177/1535370219854678

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  52 in total

1.  Genetic alterations of the WWOX gene in breast cancer.

Authors:  Seda Ekizoglu; Mahmut Muslumanoglu; Nejat Dalay; Nur Buyru
Journal:  Med Oncol       Date:  2011-10-08       Impact factor: 3.064

Review 2.  Molecularly targeted endocrine therapies for breast cancer.

Authors:  L Orlando; P Schiavone; P Fedele; N Calvani; A Nacci; P Rizzo; A Marino; M D'Amico; F Sponziello; E Mazzoni; M Cinefra; N Fazio; E Maiello; N Silvestris; G Colucci; S Cinieri
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

3.  WW domain-containing oxidoreductase: a candidate tumor suppressor.

Authors:  Nan-Shan Chang; Li-Jin Hsu; Yee-Shin Lin; Feng-Jie Lai; Hamm-Ming Sheu
Journal:  Trends Mol Med       Date:  2006-12-04       Impact factor: 11.951

Review 4.  WWOX gene and gene product: tumor suppression through specific protein interactions.

Authors:  Zaidoun Salah; Rami Aqeilan; Kay Huebner
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

Review 5.  Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase.

Authors:  Jean-Yun Chang; Ruei-Yu He; Hsin-Ping Lin; Li-Jin Hsu; Feng-Jie Lai; Qunying Hong; Shean-Jen Chen; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2010-06-11

Review 6.  Disease implications of the Hippo/YAP pathway.

Authors:  Steven W Plouffe; Audrey W Hong; Kun-Liang Guan
Journal:  Trends Mol Med       Date:  2015-02-18       Impact factor: 11.951

7.  ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.

Authors:  Taru Muranen; Laura M Selfors; Julie Hwang; Lisa L Gallegos; Jonathan L Coloff; Carson C Thoreen; Seong A Kang; David M Sabatini; Gordon B Mills; Joan S Brugge
Journal:  Cancer Res       Date:  2016-10-20       Impact factor: 12.701

8.  Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.

Authors:  Anna Göthlin Eremo; Pia Wegman; Olle Stål; Bo Nordenskjöld; Tommy Fornander; Sten Wingren
Journal:  Oncol Rep       Date:  2013-01-31       Impact factor: 3.906

9.  Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells.

Authors:  Gang Ma; Yixia Pan; Can Zhou; Ruifang Sun; Jingjing Bai; Peijun Liu; Yu Ren; Jianjun He
Journal:  Oncol Rep       Date:  2015-09-02       Impact factor: 3.906

10.  Wwox and Ap2gamma expression levels predict tamoxifen response.

Authors:  Gulnur Guler; Dimitrios Iliopoulos; Nilufer Guler; Cigdem Himmetoglu; Mutlu Hayran; Kay Huebner
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531
View more
  1 in total

1.  Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders.

Authors:  Nan-Shan Chang; Rongtuan Lin; Chun-I Sze; Rami I Aqeilan
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.